Warfarin Versus Low-Molecular-Weight Heparin Therapy in Cancer Patients

Author:

Zacharski Leo R.1,Prandoni Paolo2,Monreal Manuel3

Affiliation:

1. VA Medical and Regional Office Center, White River Junction, Vermont, USA

2. Department of Medical and Surgical Sciences, University of Padua, Padova, Italy

3. Servicio de Medicina Interna, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain

Abstract

Abstract Learning Objectives After completing this course, the reader will be able to: Define characteristics of the interface between deep vein thrombosis and malignancy. Evaluate patient factors that may complicate long-term warfarin use in patients with cancer. List advantages that may be realized with low-molecular-weight heparin (versus warfarin) therapy in cancer patients. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com The association between cancer and venous thromboembolism (VTE) is well established. Importantly, VTE is a significant cause of mortality in cancer patients. Although long-term warfarin (Coumadin™; Bristol-Myers Squibb; New York, NY) therapy is the mainstay of treatment for cancer patients with VTE, there are many practical problems with its use in this population. In particular, achieving therapeutic drug levels is difficult in cancer patients due to the increased risk of drug interactions, malnutrition, vomiting, and liver dysfunction in these patients. Moreover, cancer patients are at an increased risk of adverse effects of warfarin therapy. In contrast, low-molecular-weight heparins (LMWHs) are associated with a lower risk of adverse events compared with warfarin in patients with cancer. These agents also offer practical advantages compared with warfarin, including more predictable anticoagulant effects and ease of administration in addition to possible antineoplastic effects. Several LMWHs have demonstrated superior efficacy to warfarin in the secondary prevention of VTE. In particular, the LMWH, dalteparin (Fragmin®; Pfizer; New York, NY), has recently been shown to have superior efficacy to warfarin in a large trial of patients with cancer and VTE without increasing the risk of bleeding. A randomized trial of dalteparin has also shown improved response rates and survival in patients with small cell lung cancer. In view of the availability of more effective and reliable alternatives to warfarin therapy in cancer patients, it is appropriate to reassess the role of warfarin therapy in patients with cancer and VTE. Further evaluation of the LMWHs for effects on cancer outcome is indicated.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference49 articles.

1. Pre-operative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery;Sue-Ling;Lancet,1986

2. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis;Sproul;Am J Cancer,1938

3. Incidence of venous thromboembolism verified by necropsy over 30 years;Lindblad;BMJ,1991

4. Cancer and thromboembolic disease: pathogenic mechanisms;Lee;Cancer Treat Rev,2002

5. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?;Shen;South Med J,1980

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3